Reviewing Aradigm


Aradigm and CHF Solutions are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, institutional ownership and dividends. Aradigm has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500.



from Biotech News